SCHEMBL3036708

SCHEMBL3036708

CN(C)CCOC(=O)OCCN(C)C

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 2/20 0.65
CHRM2 P08172 1/20 0.65
CHRM4 P08173 1/20 0.65
CHRM5 P08912 1/20 0.65
CHRNB2 P17787 1/20 0.65
CHRM3 P20309 1/20 0.65
CHRNA4 P43681 1/20 0.65
CA12 O43570 2/20 0.50
CA1 P00915 2/20 0.50
CA2 P00918 2/20 0.50
CA9 Q16790 2/20 0.50
DNM1 Q05193 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
PHLPP2 Q6ZVD8 1/20 0.47
BCHE P06276 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 4/20 0.42
MAPT P10636 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL8397227 0.97 CHRM1 (0.62) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL2606265 0.91 ALDH1A1 (0.59) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL3902989 0.91 CHRM1 (0.56) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL20123407 0.89 CHRM1 (0.54) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL13407448 0.87 CHRM1 (0.58) CHRM1CHRM2CHRM4CHRM5CHRNB2
Hydrochloric Acid SCHEMBL31452986 0.87 CHRM1 (0.52) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL6840449 0.85 CHRM1 (0.50) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL15148101 0.85 CHRM1 (0.50) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL7061351 0.84 GAA (0.50) CHRM1CHRM2CHRM4CHRM5CHRNB2
SCHEMBL13123174 0.83 DNM1 (0.66) CHRM1CHRM2CHRM4CHRM5CHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1651237-A4 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS JOHNSON & JOHNSON CONSUMER (US) 2008-10-01 EP claimed
EP-1651237-A2 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS Galileo Pharmaceuticals, Inc. (US) 2006-05-03 EP claimed
WO-2005016270-A2 METHODS FOR TREATMENT OF DERMATOLOGICAL CONDITIONS GALILEO PHARMACEUTICALS, INC. (US) 2005-02-24 WO claimed
US-20050032751-A1 Methods for treatment of dermatological conditions JOHNSON & JOHNSON CONSUMER INC. 2005-02-10 US claimed
EP-0830336-B1 PROCESS FOR THE PREPARATION OF TERTIARY AMINOCARBONATES AND AMINOETHERS CROMPTON CORP (US) 2003-05-21 EP claimed
EP-0830336-A4 PROCESS FOR THE PREPARATION OF TERTIARY AMINOCARBONATES AND AMINOETHERS OSI SPECIALTIES INC (US) 2000-04-05 EP claimed
EP-0748310-B1 DIESTERS OF CARBONIC ACID ENDOWED WITH ANTIVIRAL AND ANTI-INFLAMMATORY ACTIVITY ITALFARMACO SPA (IT) 1999-06-02 EP claimed
EP-0830336-A1 PROCESS FOR THE PREPARATION OF TERTIARY AMINOCARBONATES AND AMINOETHERS OSi Specialties, Inc. (US) 1998-03-25 EP claimed
US-5686643-A FOR PRODUCING POLYURETHANES OR POLYUREAS AIR PRODUCTS AND CHEMICALS, INC. (US) 1997-11-11 US claimed
WO-1996040613-A1 PROCESS FOR THE PREPARATION OF TERTIARY AMINOCARBONATES AND AMINOETHERS OSI SPECIALTIES, INC. (US) 1996-12-19 WO claimed
US-5563288-A REACTING DIMETHYL CARBONATE WITH ALCOHOL TO FORM METHYL ALKYL CARBONATE, REACTING CARBONATE WITH TERTIARY ALKANOLAMINE OSI SPECIALTIES, INC. (US) 1996-10-08 US claimed
EP-0476785-B1 Processes for the preparation of aminoethers OSI SPECIALTIES INC (US) 1995-12-06 EP claimed
EP-0640388-A1 Magnesium/aluminum mixed oxide catalysts and their use in the production of aminoethers UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1995-03-01 EP claimed
US-5214142-A PROCESSES FOR THE PREPARATION OF AMINOETHERS UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) 1993-05-25 US claimed
EP-0476785-A1 Processes for the preparation of aminoethers OSi Specialties, Inc. (US) 1992-03-25 EP claimed
EP-3891751-A1 QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION Senda Biosciences, Inc. (US) 2021-10-13 EP disclosed
EP-2903614-B1 NOVEL COMPOUNDS, THEIR SYNTHESIS AND THEIR USES SPHAERA PHARMA PTE LTD (SG) 2021-09-29 EP disclosed
US-4845234-A IN SITU LINING OF PIPE INTERIORS, CURING AGENTS FOR EPOXY RESINS CIBA-GEIGY CORPORATION (US) 1989-07-04 US disclosed
US-4772695-A DEHYDROHALOGENATION, INSECTICIDES SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1988-09-20 US disclosed
US-4762585-A EPOXY RESINS WITH AMINE CURING AGENTS CIBA-GEIGY CORPORATION (US) 1988-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032751-A1 Methods for treatment of dermatological conditions KRT18, CUTA, TUBB1 CHRM1 4334/4885CHRM2 3645/4885CHRM4 4225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.